Orexa is a clinical-stage pharmaceutical company that develops therapeutics to increase food intake. Its lead compound is a proprietary oral formulation for human use, based on a well known anesthetic.
The company has started its first phase 2 study, in the prevention of Post-Operative Ileus, with the first patient dosed in January 2024, and its second phase 2 study, in Anorexia Nervosa, with expected inclusion of the first patient in Q2-2024.
Further, it is in preparation of a third phase 2 study in Cachexia. In all these three indications increased food intake could lead to an improved patient health, a shorter hospital stay and significant cost savings.
Orexa was founded in 2016 and is headquartered in Herpen (Oss Region, Noord Brabant), The Netherlands.
Acting CEO / CFO
Actuarial Sciences (University of Amsterdam)
Early investor in AM-Pharma.
CFO of Alloksys Life Sciences
Venture Partner of NextStage Early Stage Fund
CSO / Founder of Orexa
PhD in Psychology
Professor in Behavioural Pharmacology (Radboud UMC, Nijmegen)
Organon, Schering Plough, MSD
Within Organon Ard was responsible for the development of brain active (CNS) drugs.
“We have found a very strong signal in our pre-clinical research and successfully completed a Phase 1 study.
Now we are in the most exciting stage: will our mechanism of action also work in patients in Phase 2 ?”
Prof. Dr. Ard Peeters